On November 2, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported financial results for the quarter ended September 30, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications," said Eric Lefkofsky, founder and CEO of Tempus. "These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter."
Third Quarter 2026 Highlights
For the three-month period ended September 30, 2026, as compared to the same period in 2025:
Total revenue of $411.5 million, an increase of 23%
Oncology volume growth accelerated to 32%
Minimal Residual Disease (MRD) volume of ~12,000 tests, up 300%
Data & Apps revenue increased 33%, with Insights increasing 29%
Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and expect full year Adjusted EBITDA of ~$65 million
Announced multi-year strategic collaboration with Merck and Moderna to support commercialization of their individualized neoantigen therapy (INT) class of drugs
In October, announced a strategic collaboration with BMS bringing Tempus’ total data licensing bookings to >$550 million year to date
Third Quarter 2026 Summary Results
For the three-month period ended September 30, 2026, as compared to the same period in 2025:
Total revenue increased 23% to $411.5 million.
Diagnostics generated $303.5 million of revenue, representing 20% growth, driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 3%.
Data and Applications generated $108.1 million of revenue, representing 33% growth, with Insights growing 29%.
Gross profit increased 27% to $266.7 million, led by growth in Data and Applications.
Net loss was $(14.9) million, which included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities, compared to a net loss of $(80.0) million in Q3 of 2025.
Adjusted EBITDA was $25.6 million, compared to $1.5 million in Q3 of 2025.
Ended the quarter with cash and marketable securities of $854.4 million.
Detailed Operational Highlights
Announced a strategic collaboration with BMS in October through which Tempus is directly licensing to BMS oncology data and models for up to $137.5 million over a five-year term. In addition, BMS and Pathos are licensing data for patients with Alzheimer’s or dementia for $55 million over a five-year term, extending Tempus’ data and modeling platform beyond oncology.
Announced a multi-year strategic collaboration with Merck and Moderna to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completed resected stage IIB-IV melanoma and other cancer types.
Cleared regulatory review of pending acquisition of Personalis (Nasdaq: PSNL). Personalis’ shareholder meeting to approve the acquisition is planned for November 30, 2026.
Received two 510(k) clearances from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH and ECG-MR, expanding our non-invasive AI cardiology footprint.
Announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years.
Third Quarter Financial Results
Three Months Ended September 30,
2026
2025
Change
(in thousands, except percentages and per share amounts)
(unaudited)
Revenue
$
411,537
$
334,206
23
%
Gross profit
$
266,701
$
209,942
27
%
Loss from operations
$
(56,864
)
$
(60,996
)
7
%
Non-GAAP income (loss) from operations
$
14,422
$
(8,662
)
267
%
Net loss
$
(14,851
)
$
(79,982
)
81
%
Non-GAAP net income (loss)
$
13,359
$
(19,590
)
168
%
Adjusted EBITDA
$
25,572
$
1,476
1,633
%
Net loss per share, basic and diluted
$
(0.08
)
$
(0.46
)
83
%
Non-GAAP net income (loss) per share, basic and diluted
$
0.07
$
(0.11
)
164
%
Financial Outlook and Guidance
Tempus is increasing its full year 2026 revenue guidance to $1.60 to $1.605 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million.
For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.
Webcast and Conference Call Information
A conference call and webcast will begin today, November 2, 2026 at 8:45 a.m. Eastern Time. Interested parties may access details at:
Conference ID: 579 261 752
United States (Toll-Free): (833) 461-5787
International (Toll): +1 (585) 542-9983
Live webcast can be accessed here
The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference call and webcast.
(Press release, Tempus, NOV 2, 2026, View Source [SID1234674061])